💪 Scilex Holding Company is re-engineering pain management. 🔬 Headquartered in Palo Alto, CA, $SCLX is an innovative pharmaceutical company focused on non-opioid pain management products. 🎉 Today we’re celebrating the launch of Gloperba®, the first and only liquid oral version of anti-gout medicine. Congratulations! #NasdaqListed
Nasdaq’s Post
More Relevant Posts
-
Amanda Malone at Eupraxia Pharmaceuticals Inc. is presenting the data from Phase 2 #osteoarthritis trial results. It is great to see the success of EP-104IAR (Extended-Release Fluticasone Propionate for Injectable Suspension) in this study and discuss how this product can impact patient pain and function at #ACR23, with Dr. Olga Kubassova, Mikael Boesen and Asger Bihlet. #rheumatology #osteoarthritis #success #pain #steroids
To view or add a comment, sign in
-
If you missed our "Targeted Pain Treatment" webinar, please enjoy the recording of that discussion. Special thanks to our guest speakers Stephanie G. Vanterpool MD, MBA, FASA and Scott Chappell of Galt Pharmaceuticals. #targetedpaintreatment #painmanagement https://lnkd.in/ejy4dTXt
"Targeted Pain Treatment" feat. Dr. Stephanie Vanterpool and Scott Chappell of GALT Pharmaceuticals
https://www.youtube.com/
To view or add a comment, sign in
-
In recent years, the field of pain management has witnessed a remarkable transformation, marked by groundbreaking innovations that promise to revolutionize the way we address and alleviate pain. From cutting-edge pharmaceutical developments and minimally invasive procedures to advanced neuromodulation techniques and integrative therapies, a new era of pain relief has dawned. https://lnkd.in/dk7ERVQj
To view or add a comment, sign in
-
Interesting insights from the Crumdale Partners conference. What’s your strategy to control high cost specialty medications? 2023 NEW APPROVALS The FDA approved a milestone 67 New drugs in 2023 predominately orphan & breakthrough therapies. 55 specialty & 12 traditional. - Zepbound (Weight Loss) - Bimzlex (Psoriasis) - Omvoh, Velsipity (UC) - Zurzuvae (Post-partum dep.) - Exxua (Depression) - Opill (First OTC O/C) - 5 Unique Biosimilars (9 Humira) 2024-2025 DRUG PIPELINE - fenebrutinib, tolebrutinib (MS) - ansofaxine (Depression) - donanemab (Alzheimer's) - semaglutide-oral, retatrutide - orforglipron (Weight Loss)
To view or add a comment, sign in
-
#DYK that 1 out of 2 #lupus patients will develop lupus nephritis? For more information on #lupusnephiritis, check out the event we hosted yesterday in collaboration with Aurinia Pharmaceuticals. #LAM24 #LupusAwarenessMonth
To view or add a comment, sign in
-
Our department's groundbreaking research on 'A Comparative Study of Metformin versus Metformin + Myo-Inositol Combination and Effect of Lifestyle Intervention in Polycystic Ovarian Disease Patients' has been published in the International Journal of Pharmacy and Pharmaceutical Research. Thrilled to contribute to advancements in PCOS management. #Research #PCOS #Healthcare"
To view or add a comment, sign in
-
#NewDrug Alert- The second Stelara biosimilar, Selarsdi, was approved on 4/16/24. But now we still wait! Anticipating Wezlana, approved 10/31/23 to launch 1/1/25, as interchangeable. Selarsdi and up to 2 others to follow at the end of February 2025. 🤞 for a quicker uptake than what we saw with Humira biosimilars! Some PBMs are already taking about the aggressive stance they plan on taking earlier with their lessons learned. Hopefully this translates to more savings quicker. #Pharmacists #Pharmacybenefits #biosimilars #PBM https://lnkd.in/g2uUir6Z
To view or add a comment, sign in
-
Surrozen has decided to halt further development of its inflammatory bowel disease (IBD) therapy, SZN-1326. Challenges in determining a safe and effective dosage, along with the competitive landscape in the pharmaceutical market, have led to this strategic shift. This decision marks a significant development for Surrozen and its efforts to address IBD. #Surrozen #ibd #drugdevelopment #therapy #healthcare #lifesciences
To view or add a comment, sign in
-
Madrigal Pharmaceuticals, Hepion Pharmaceuticals, and 89Bio are leading contenders in the quest for the first treatment, but the recent regulatory setback faced by Intercept Pharmaceuticals' obeticholic acid tablets has raised important safety concerns in the field. Stay tuned as these pioneering companies vie for breakthrough solutions to combat NASH, a serious liver disease affecting millions worldwide. https://lnkd.in/eG_fdDfD #NASHTreatment #MedicalInnovation #LiverHealth #PharmaceuticalAdvancements #SafetyConcerns #PioneeringResearch #HealthcareNews #MedicalBreakthroughs #StayInformed #RaceToCureNASH
To view or add a comment, sign in
472,244 followers
IT Support Specialist at Scilex Holding Company
2wAwesome company!